Background
After deep brain stimulation (DBS) for Parkinson’s disease (PD), changing medication doses may affect vision. However, no studies have specifically looked at this issue.
Objectives
This study aimed to compare the impact of reducing medication doses (levodopa-equivalent daily dose, or LEDD) on vision in PD patients after DBS.
Methods
In this clinical trial, 208 PD patients were enrolled from June 2019 to July 2021. They were divided into two groups: one group had their LEDD reduced, while the other did not. Vision was assessed 12 months after surgery using a questionnaire and other eye tests.
Results
In the short term, DBS did not significantly affect vision. However, in the long term, patients who had their LEDD reduced experienced worse vision and changes in eye structure compared to those who did not reduce their medication.
Conclusions
Reducing LEDD after DBS is linked to worsening vision. Continuing dopamine medications may help prevent these visual issues. Doctors should be mindful of adjusting medication doses if patients report vision problems before or after surgery.
Opportunities for Improvement
- Define Measurable Outcomes: Establish clear goals to monitor vision changes related to LEDD adjustments.
- Select AI Tools: Choose AI solutions that meet specific clinical needs for tracking patient outcomes.
- Implement Step by Step: Start with a pilot project to track results, using AI to analyze the impact of LEDD changes on vision.
Contact Us for AI Solutions in Medical Management
For more information, reach out via:
